1. Drug resistance in multiple myeloma. (November 2018) Authors: Robak, Pawel; Drozdz, Izabela; Szemraj, Janusz; Robak, Tadeusz Journal: Cancer treatment reviews Issue: Volume 70(2018) Page Start: 199 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Issue 2 (February 2022) Authors: Schjesvold, Fredrik H; Dimopoulos, Meletios-Athanasios; Delimpasi, Sosana; Robak, Pawel; Coriu, Daniel; Legiec, Wojciech; Pour, Luděk; Špička, Ivan; Masszi, Tamas; Doronin, Vadim; Minarik, Jiri; Salogub, Galina; Alekseeva, Yulia; Lazzaro, Antonio; Maisnar, Vladimir; Mikala, Gábor; Rosiñol, Laura;... Journal: Lancet Issue: Volume 9:Issue 2(2022) Page Start: e98 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Mantle cell lymphoma: therapeutic options in transplant-ineligible patients. Issue 11 (19th September 2019) Authors: Robak, Tadeusz; Smolewski, Piotr; Robak, Pawel; Dreyling, Martin Journal: Leukemia & lymphoma Issue: Volume 60:Issue 11(2019) Page Start: 2622 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Immunotherapy combinations for chronic lymphocytic leukemia: advantages and disadvantages. (2nd January 2023) Authors: Robak, Pawel; Robak, Tadeusz Journal: Expert opinion on biological therapy Issue: Volume 23:Number 1(2023) Page Start: 21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Issue 6 (June 2019) Authors: Richardson, Paul G; Oriol, Albert; Beksac, Meral; Liberati, Anna Marina; Galli, Monica; Schjesvold, Fredrik; Lindsay, Jindriska; Weisel, Katja; White, Darrell; Facon, Thierry; San Miguel, Jesus; Sunami, Kazutaka; O'Gorman, Peter; Sonneveld, Pieter; Robak, Pawel; Semochkin, Sergey; Schey, Steve; Y... Journal: Lancet oncology Issue: Volume 20:Issue 6(2019) Page Start: 781 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia. Issue 10 (October 2010) Authors: Robak, Tadeusz; Lech-Maranda, Ewa; Robak, Pawel Journal: Expert review of anticancer therapy Issue: Volume 10:Issue 10(2010) Page Start: 1529 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia. Issue 10 (October 2010) Authors: Robak, Tadeusz; Lech-Maranda, Ewa; Robak, Pawel Journal: Expert review of anticancer therapy Issue: Volume 10:Issue 10(2010) Page Start: 1529 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Bone lesions in hairy cell leukemia: Diagnosis and treatment. (19th August 2020) Authors: Robak, Pawel; Jesionek‐Kupnicka, Dorota; Kupnicki, Piotr; Polliack, Aaron; Robak, Tadeusz Journal: European journal of haematology Issue: Volume 105:Number 6(2020) Page Start: 682 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. Issue 10262 (14th November 2020) Authors: Grosicki, Sebastian; Simonova, Maryana; Spicka, Ivan; Pour, Ludek; Kriachok, Iryrna; Gavriatopoulou, Maria; Pylypenko, Halyna; Auner, Holger W; Leleu, Xavier; Doronin, Vadim; Usenko, Ganna; Bahlis, Nizar J; Hajek, Roman; Benjamin, Reuben; Dolai, Tuphan K; Sinha, Dinesh K; Venner, Christopher P; G... Journal: Lancet Issue: Volume 396:Issue 10262(2020) Page Start: 1563 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. BCR Signaling in Chronic Lymphocytic Leukemia and Related Inhibitors Currently in Clinical Studies. (1st August 2013) Authors: Robak, Tadeusz; Robak, Pawel Journal: International reviews of immunology Issue: Volume 32:Number 4(2013:Aug.) Page Start: 358 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗